EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 308 participants.

Also called NCT03287609

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 308 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03287609
Other papers using this trial's data
  • Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS) Journal of the American College of Cardiology, 2019-11-19 DOI, PubMed 31479722

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Switzerland (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03287609. Randomized; quadruple masking; primary purpose treatment. Start 2018-01-23 (actual); primary completion 2019-05-20 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS)
Acronym
EVOPACS
Condition
Acute Coronary Syndrome
Intervention (Drug)
Evolocumab 140 mg/mL
Intervention (Drug)
Placebo
Lead sponsor
Insel Gruppe AG, University Hospital Bern (class: other)
Collaborator
Amgen (class: industry)
Collaborator
University of Bern (class: other)

Record details

Record id
cardio:ct-nct03287609
Content hash
bbb4f0d7c2829401249a078a570e3da3d9dbd8bc907281e567f3b3ec53dac656